Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2024-02-14 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter from Bafna Pharmaceuticals Limited addressed to stock exchanges, providing newspaper clippings as evidence of the publication of un-audited financial results for the third quarter and nine months ended December 31, 2023. It states that the results were approved by the Board and published in newspapers. The document is short (2109 characters) and serves as an announcement or intimation regarding the publication of financial results, not the financial report itself. It references the financial results but does not contain the actual financial data or detailed analysis. Therefore, it fits the criteria of a Regulatory Filing (RNS) as a general regulatory announcement and intimation under SEBI regulations, rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2024-02-14 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a letter from Bafna Pharmaceuticals Limited to stock exchanges reporting the outcome of a Board meeting held on February 12, 2024. It announces the approval of the unaudited financial results for the quarter ended December 31, 2023, prepared under Indian Accounting Standards (Ind AS). The letter includes the unaudited standalone financial results and the Limited Review Report issued by the statutory auditor. The document references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results. The presence of unaudited financial statements and a limited review report for a quarter indicates this is an Interim / Quarterly Report. The document length (9904 characters) and content show it contains substantive financial data and analysis, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2024
2024-02-13 English
Outcome of Board Meeting
Regulatory Filings
2024-02-12 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter from Bafna Pharmaceuticals Limited addressed to stock exchanges, informing about a scheduled Board of Directors meeting to approve the Q3 FY24 unaudited standalone financial results and the limited review report. It references regulatory compliance under SEBI listing obligations and insider trading regulations. The document does not contain the financial results themselves but is an announcement of the upcoming approval meeting for these results. The document length is short (2331 characters), and it serves as an intimation or notice rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2024-02-02 English
Board Meeting — BAFNA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company…
Regulatory Filings
2024-02-02 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter from Bafna Pharmaceuticals Limited to stock exchanges submitting a certificate from their Registrar and Share Transfer Agent (RTA) in compliance with Regulation 74(5) of SEBI (Depository & Participants) Regulations, 2018, for the quarter ended December 31, 2023. The certificate confirms dematerialization of share certificates within prescribed timelines. The document is short (3424 characters) and primarily serves as a compliance submission and confirmation letter rather than a financial report or detailed filing. It does not contain financial statements or detailed financial data. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement or compliance document that does not fit other specific categories.
2024-01-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.